Bronchopulmonary aspergillosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bronchopulmonary aspergillosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of inhaled liposomal amphotericin B and technetium-99m to assess lung distribution in patients with chronic pulmonary aspergillosis https://clinicaltrials.eu/trial/study-of-inhaled-liposomal-amphotericin-b-and-technetium-99m-to-assess-lung-distribution-in-patients-with-chronic-pulmonary-aspergillosis/ Wed, 29 Apr 2026 15:07:30 +0000 https://clinicaltrials.eu/trial/study-of-inhaled-liposomal-amphotericin-b-and-technetium-99m-to-assess-lung-distribution-in-patients-with-chronic-pulmonary-aspergillosis/ This study focuses on patients with Chronic Pulmonary Aspergillosis, a fungal infection that affects the lungs. The research examines a treatment called AmBisome, which contains liposomal amphotericin B, a medication used to treat fungal infections. The treatment will be combined with a radioactive substance called Technetium-99m and given through inhalation using a nebulizer, which turns the medication into a fine mist that can be breathed in.

The main purpose of this study is to understand how the inhaled medication spreads throughout the lungs and to find the best way to give this treatment. During the study, special imaging called single-photon emission computed tomography will be used to see where the medication goes in the lungs. The researchers will also measure how much of the medication gets into the blood.

The treatment will be given over two days through a nebulizer. Throughout the study, the researchers will monitor how well patients tolerate the treatment and any side effects they may experience. They will also ask patients about their satisfaction with the treatment and how convenient it is to use.

]]> Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options https://clinicaltrials.eu/trial/effectiveness-and-safety-of-rezafungin-in-adults-with-chronic-pulmonary-aspergillosis-who-have-limited-treatment-options/ Wed, 29 Apr 2026 15:06:13 +0000 https://clinicaltrials.eu/trial/effectiveness-and-safety-of-rezafungin-in-adults-with-chronic-pulmonary-aspergillosis-who-have-limited-treatment-options/ This study evaluates the effectiveness and safety of rezafungin for treating chronic pulmonary aspergillosis (CPA), a long-term fungal infection that affects the lungs. The research focuses on adult patients who have limited treatment options, particularly those who cannot receive the standard azole antifungal therapy. Rezafungin is being studied as an alternative medication for patients whose condition is progressing or who have significant symptoms from this fungal lung infection.

The purpose is to determine if six months of rezafungin treatment can improve the condition of patients with CPA who have few treatment alternatives. During the study, patients will receive rezafungin and be monitored for changes in their respiratory symptoms, weight, and lung condition through computed tomography (CT) imaging, which uses X-rays to create detailed pictures of the lungs. Patients will also complete questionnaires about their breathing symptoms and quality of life.

The study will track how participants respond to the medication by measuring changes in their Aspergillus antibody levels (indicators of the fungal infection), need for additional medications, hospitalizations, and any side effects that may occur during treatment. This is a phase 2 study, which means it aims to gather preliminary data on whether the medication works for this specific condition and what side effects might occur.

]]> Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-opelconazole-with-other-antifungal-treatments-for-patients-with-hard-to-treat-lung-aspergillosis/ Wed, 29 Apr 2026 15:02:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-opelconazole-with-other-antifungal-treatments-for-patients-with-hard-to-treat-lung-aspergillosis/ This clinical trial is focused on studying a condition known as Refractory Invasive Pulmonary Aspergillosis, which is a serious lung infection that does not respond well to standard treatments. The study is testing a new treatment called PC945, which contains the active substance opelconazole. This treatment is delivered as a nebulizer suspension, meaning it is inhaled as a mist directly into the lungs. The trial will compare the effects of PC945 when used alongside other antifungal medications to a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate the safety and effectiveness of PC945 in combination with other antifungal therapies. Participants in the study will receive either the PC945 treatment or a placebo, in addition to their existing antifungal therapy. The study will last for up to 12 weeks, during which time researchers will monitor the participants’ responses to the treatment.

Throughout the study, the main focus will be on observing how well the treatment works in improving the condition of those with refractory invasive pulmonary aspergillosis. The goal is to determine if adding PC945 to the current treatment regimen can help achieve a better overall response in managing this challenging lung infection.

]]> Study on Imaging Lung Aspergillosis Using Gallium-68 Deferoxamine for Patients with Pulmonary Aspergillosis https://clinicaltrials.eu/trial/study-on-imaging-lung-aspergillosis-using-gallium-68-deferoxamine-for-patients-with-pulmonary-aspergillosis/ Wed, 29 Apr 2026 14:30:05 +0000 https://clinicaltrials.eu/trial/study-on-imaging-lung-aspergillosis-using-gallium-68-deferoxamine-for-patients-with-pulmonary-aspergillosis/ This clinical trial is focused on studying a lung infection called pulmonary aspergillosis. This condition is caused by a type of fungus that can affect the lungs, leading to various respiratory issues. The study is exploring a new way to visualize this infection using a special imaging technique. The treatment being tested involves a combination of two substances: deferoxamine mesilate and gallium (68Ga) chloride. These substances are combined to form a compound called 68Ga-DFO, which is used in a type of scan known as a PET/CT scan. This scan helps doctors see the infection in the lungs more clearly.

The purpose of the study is to see if this new imaging method can effectively show the presence of the fungal infection in the lungs. Participants in the study will receive the 68Ga-DFO compound through an intravenous injection, which means it is given directly into a vein. After the injection, a PET/CT scan will be performed to capture detailed images of the lungs. This process is expected to take place over a short period, typically within a day.

The study aims to gather information on how well the 68Ga-DFO compound highlights the infection in the lungs. Researchers will look at how the compound is taken up in different parts of the lungs and compare it to various factors like iron levels in the body and the presence of other infections. This research could lead to better ways of diagnosing and understanding pulmonary aspergillosis, potentially improving treatment options for those affected by this condition.

]]> Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis https://clinicaltrials.eu/trial/study-comparing-itraconazole-and-nebulised-amphotericin-b-with-itraconazole-alone-for-patients-with-chronic-pulmonary-aspergillosis/ Wed, 29 Apr 2026 14:22:50 +0000 https://clinicaltrials.eu/trial/study-comparing-itraconazole-and-nebulised-amphotericin-b-with-itraconazole-alone-for-patients-with-chronic-pulmonary-aspergillosis/ This clinical trial is focused on studying the treatment of Chronic Pulmonary Aspergillosis, a lung condition caused by a type of fungus called Aspergillus. The study aims to compare the effectiveness of two treatment approaches over a six-month period. One group of patients will receive a combination of two medications: itraconazole, which is taken orally, and AmBisome, which is inhaled. The other group will receive only itraconazole. The purpose of the study is to determine which treatment is more effective in improving the health of patients with this condition.

Participants in the study will be monitored for six months while receiving their assigned treatment. During this time, doctors will assess both clinical and radiological improvements, which means they will look for signs of better health and changes in lung images. After the treatment period, there will be a follow-up for 24 months to observe any long-term effects or relapses. The study will also evaluate the quality of life of participants using a questionnaire and track any major health events or hospital visits related to respiratory symptoms.

The study is designed for patients who are not severely immunocompromised, meaning their immune systems are not significantly weakened. It excludes those with a single aspergilloma, which is a specific type of fungal growth in the lungs. The trial is conducted in a single-blind manner, meaning that the patients do not know which treatment group they are in, but the researchers do. This helps ensure that the results are unbiased and reliable.

]]>